Clinical
HSDD
Hypoactive sexual desire disorder — the FDA-approved indication for PT-141.
Definition
HSDD is characterized by persistently reduced or absent sexual interest causing personal distress. PT-141 (bremelanotide) was approved for premenopausal HSDD in 2019.
Related terms
Back to the full peptide glossary.